Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
What a time it’s been for Integra LifeSciences. In the past six months alone, the company’s stock price has increased by a massive 70.2%, reaching $16.26 per...
Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumabl...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Integra LifeSciences’ second quarter results reflected ongoing business challenges, as management attributed the quarter’s flat revenue to ongoing reimbursem...
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 mil...
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 10.1% in the afternoon session after the company reported a second-qu...
Integra LifeSciences (NASDAQ:IART) reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, ex
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 mil...
Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results this Wednesday morning. Here’s what to look for. Integra LifeSc...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) jumped 4.3% in the afternoon session after BMO Capital initiated coverage ...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Over the past six months, Integra LifeSciences has been a great trade, beating the S&P 500 by 25.3%. Its stock price has climbed to $17.91, representing a he...
What Happened? Shares of medical device company Integra LifeSciences (NASDAQ:IART) jumped 6.1% in the afternoon session after Citigroup upgraded its rating o...
